Efficacy and safety of sofosbuvir/belpatasvir combination tablets for patients infected with pan-genotypic hepatitis C virus
Not Applicable
- Conditions
- Chronic liver disease infected with HCV
- Registration Number
- JPRN-UMIN000035625
- Lead Sponsor
- Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who do not have consent to clinical research 2) Patietns accompanying HCC 2) Patients with pregnancy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rates of Sustained virological response at 12 and 24 weeks after the end of treatment
- Secondary Outcome Measures
Name Time Method